Key result
Increased cerebral blood flow in the middle and posterior cingulate after 12 weeks of venlafaxine treatment was significantly associated with decreased depressive symptoms (family-wise error P<0.05).
Why the study?
Does venlafaxine treatment alter cerebral blood flow in older patients with major depressive disorder?
Population
Older patients (≥ 50 years of age; N = 46; 29 female) with a DSM-IV diagnosis of major depressive disorder
Comparison
Venlafaxine treatment for 12 weeks vs Baseline and placebo (within-subject comparison)
Design
Cohort
Follow-up
12 weeks
Authors
Loading...
Should not alter venlafaxine prescribing; leaves open cingulate perfusion as a potential response biomarker.
Does venlafaxine treatment alter cerebral blood flow in older patients with major depressive disorder?
p-value: p=<.05
Regional cerebral blood flow increases in the middle and posterior cingulate are associated with decreases in depressive symptoms following venlafaxine treatment in late-life depression.
Wei et al. (2018) studied major depressive disorder (n=46). Venlafaxine vs. Baseline was evaluated on Association between changes in depression severity (MADRS score) and changes in voxel-wise cerebral blood flow (p=<.05). Increased cerebral blood flow in the middle and posterior cingulate after 12 weeks of venlafaxine treatment was significantly associated with decreased depressive symptoms (family-wise error P<0.05).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: